Alvotech Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6
Alvotech şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler
n/a
Temettü verimi
-8.8%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -8.8% |
| Gelecekteki Temettü Verimi | 0% |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü ve geri alım güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • Aug 07
ALVO: FDA Inspection Closure And Biosimilar Resubmissions Will Drive Upside
Analysts have reset their view on Alvotech with a lower implied fair value, moving from about $13.83 to $5.75, as they factor in slightly different assumptions on growth, profitability, and future P/E levels. What’s in the News for Alvotech Alvotech reported that the FDA has closed its May 2026 inspection of the Reykjavik manufacturing facility with a Voluntary Action Indicated classification, following actions taken by the company to address all observations.
Anlatı Güncellemesi • Jul 24
ALVO: Regulatory Progress And Capital Raises Will Support Future Upside
Analysts have reset their 12 month price target on Alvotech from $50.00 to $9.50, citing updated assumptions for long term revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Alvotech Closed an amended private placement on July 1, 2026, raising total gross proceeds of US$175 million, including participation from funds managed by GoldenTree Asset Management LP and other existing lenders.Anlatı Güncellemesi • Jul 07
ALVO: Biosimilar Advances And Fresh Capital Raises Will Drive Future Upside
Analysts have revised their price target on Alvotech to $50.00, citing updated assumptions for revenue growth, profit margins, and a lower discount rate, which also leads to a reduced future P/E multiple in their models. What’s in the News for Alvotech Alvotech completed a series of capital raises, including a $125 million public offering and related transactions, with some analysts suggesting the stock may appear undervalued based on certain valuation measures, source: Alvotech stock offering coverage.
Anlatı Güncellemesi • Jun 23
ALVO: 2026 Guidance Balanced By Capital Raise And Regulatory Milestones
Analysts have adjusted their price target on Alvotech to $4.00. The updated view reflects slightly lower discount rate assumptions, a modestly higher revenue growth outlook and profit margin expectations, and a marginally lower future P/E multiple.Seeking Alpha • Jun 08
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements
Summary Alvotech remains a commercial-stage biosimilar company with real revenue, partners, and a growing global footprint. I believe its main upside potential lies with the resubmission of AVT05 and AVT06 after its recent manufacturing delays in the US. ALVO’s valuation has been punished by regulatory setbacks in its manufacturing facilities. So if those concerns are resolved, the stock could quickly re-rate higher. However, there are also substantial risks related to its cash burn and runway until we see ALVO’s optimistic guidance materialize later this year. In my view, ALVO is a viable speculative "Buy" for investors who believe ALVO will ultimately satisfy the FDA’s CMC requirements. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 06
ALVO: FDA Resubmissions And 2026 Biosimilar Launch Plan Will Drive Upside
Analysts have trimmed their average price target on Alvotech to about $13.83 from $14.00, linking the change to updated views on future P/E assumptions, as well as adjusted expectations for revenue growth and profit margins. Analyst Commentary Recent Street research on Alvotech points to a mixed but focused view on the stock, with several firms adjusting price targets and updating their assumptions around P/E, revenue growth, and margins.Anlatı Güncellemesi • May 19
ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside
Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.Anlatı Güncellemesi • Apr 29
ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside
Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.Anlatı Güncellemesi • Apr 15
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.Anlatı Güncellemesi • Mar 31
ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside
Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.Anlatı Güncellemesi • Mar 17
ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside
Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.Anlatı Güncellemesi • Mar 03
ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside
Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.Anlatı Güncellemesi • Feb 17
ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook
Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.Anlatı Güncellemesi • Feb 03
ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside
Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.Anlatı Güncellemesi • Jan 20
ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook
Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.Anlatı Güncellemesi • Jan 05
ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile
Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.Anlatı Güncellemesi • Dec 17
ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside
Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.Anlatı Güncellemesi • Dec 03
ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside
Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.Analiz Makalesi • Nov 20
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Even though Alvotech ( NASDAQ:ALVO ) posted strong earnings recently, the stock hasn't reacted in a large way. We...Anlatı Güncellemesi • Nov 19
ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade
Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.Analiz Makalesi • Nov 09
Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
Alvotech ( NASDAQ:ALVO ) shareholders that were waiting for something to happen have been dealt a blow with a 31% share...Analiz Makalesi • Nov 06
Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers
Market forces rained on the parade of Alvotech ( NASDAQ:ALVO ) shareholders today, when the analysts downgraded their...Anlatı Güncellemesi • Nov 05
ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks
Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.Analiz Makalesi • May 25
Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%
Those holding Alvotech ( NASDAQ:ALVO ) shares would be relieved that the share price has rebounded 29% in the last...Analiz Makalesi • May 15
Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations
Unsurprisingly, Alvotech's ( NASDAQ:ALVO ) stock price was strong on the back of its healthy earnings report. However...Yeni Anlatı • May 05
Biosimilar Pipeline And R&D Capability Will Open New Markets
Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.Analiz Makalesi • Apr 08
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet
Unfortunately for some shareholders, the Alvotech ( NASDAQ:ALVO ) share price has dived 25% in the last thirty days...Seeking Alpha • Nov 21
Alvotech's Position In The Coming Biosimilar Gold Rush
Summary Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector. While facing risks like competition and partner dependency, Alvotech's strategic focus and operational scalability offer considerable growth potential for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Alvotech: Steady Progress Offers A Good Chance Of Upside
Summary Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million. With revenues of $600 million to $800 million promised in 2025, Alvotech stock stands a good chance of realising upside in the second half of 2024. Read the full article on Seeking AlphaÖdemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: ALVO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: ALVO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi
| Alvotech Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (ALVO) | n/a |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.1% |
| Sektör Ortalaması (Biotechs) | 2.2% |
| Analist tahmini (ALVO) (3 yıla kadar) | 0% |
Önemli Temettü: ALVO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ALVO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: ALVO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: ALVO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/11 19:40 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Alvotech 10 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Glen Santangelo | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Andrew Baum | Citigroup Inc |